TCGA-CN-A49B-01A-31R-A24H-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- INTERFERON_GAMMA_RESPONSE+0.580
- TNFA_SIGNALING_VIA_NFKB+0.490
- ALLOGRAFT_REJECTION+0.460
- E2F_TARGETS+0.460
- MYC_TARGETS_V2+0.450
- OXIDATIVE_PHOSPHORYLATION+0.440
- MYC_TARGETS_V1+0.420
- IL6_JAK_STAT3_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.400
Top 10 suppressed
- MYOGENESIS-0.260
- BILE_ACID_METABOLISM-0.220
- MITOTIC_SPINDLE-0.130
- APICAL_SURFACE-0.100
- FATTY_ACID_METABOLISM-0.090
- WNT_BETA_CATENIN_SIGNALING-0.090
- HEME_METABOLISM-0.070
- KRAS_SIGNALING_DN-0.050
- UV_RESPONSE_DN-0.050
- APICAL_JUNCTION-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.911 |
| 2 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.887 |
| 3 | BS_GJNCYABP | ATRT | — | 0.886 |
| 4 | TCGA-G2-A2ES-01A-11R-A180-07 | — | — | 0.884 |
| 5 | 788A8487-6A02-4BF5-8E84-16BE5D92BF0F | — | — | 0.878 |
| 6 | MDT-AP-0826 | Med | Medulloblastoma | 0.877 |
| 7 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.876 |
| 8 | SRR934888 | — | — | 0.875 |
| 9 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.874 |
| 10 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |